Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1825 of 2873 entries
View as:

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00081874 Org: User:
Start: 04/30/04 End: 09/30/06 Due: 09/30/07

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02491632 Org: User:
Start: 08/13/15 End: 12/31/26 Due: 12/31/27

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase: N/A Priority: Normal
NCT ID: NCT04216472 Org: User:
Start: 02/05/20 End: 12/31/25 Due: 12/31/26

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00427765 Org: User:
Start: 12/31/04 End: 11/30/10 Due: 11/30/11

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04973683 Org: User:
Start: 09/30/21 End: 12/15/25 Due: 12/15/26

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03015740 Org: User:
Start: 04/23/17 End: 09/06/22 Due: 09/06/23

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02321540 Org: User:
Start: 03/31/15 End: 09/16/21 Due: 09/16/22

Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients

Phase: N/A Priority: Normal
NCT ID: NCT00504920 Org: User:
Start: 05/31/04 End: 09/30/08 Due: 09/30/09

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Phase: N/A Priority: Normal
NCT ID: NCT00967369 Org: User:
Start: 08/24/09 End: 05/02/18 Due: 05/02/19

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00003311 Org: User:
Start: 05/20/98 End: 04/18/07 Due: 04/18/08

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Phase: N/A Priority: Normal
NCT ID: NCT00082719 Org: User:
Start: 12/31/03 End: 01/31/15 Due: 01/31/16

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02659241 Org: User:
Start: 02/04/16 End: 12/31/26 Due: 12/31/27

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04915612 Org: User:
Start: 05/21/21 End: 01/30/25 Due: 01/30/26

A Pilot Clinical Trial to Determine the Feasibility of Administering an Electronic Tool to Assess Postoperative pAin, Nausea, and Vomiting in English or Spanish-Speaking Pediatric Patients With Neoplastic Conditions.

Phase: N/A Priority: Normal
NCT ID: NCT05933252 Org: User:
Start: 06/19/23 End: 04/21/25 Due: 04/21/26

What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care

Phase: N/A Priority: Normal
NCT ID: NCT04794816 Org: User:
Start: 01/21/21 End: 10/31/25 Due: 10/31/26

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

Phase: N/A Priority: Normal
NCT ID: NCT06066437 Org: User:
Start: 03/29/24 End: 12/31/27 Due: 12/31/28

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03359954 Org: User:
Start: 11/16/17 End: 10/31/25 Due: 10/31/26

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05336383 Org: User:
Start: 05/31/22 End: 12/07/26 Due: 12/07/27

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02910700 Org: User:
Start: 12/09/16 End: 12/08/25 Due: 12/08/26

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Phase: N/A Priority: Normal
NCT ID: NCT05317936 Org: User:
Start: 11/16/22 End: 10/01/27 Due: 10/01/28

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04505254 Org: User:
Start: 08/25/20 End: 06/30/27 Due: 06/30/28

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Phase: N/A Priority: Normal
NCT ID: NCT01134575 Org: User:
Start: 06/04/10 End: 04/18/18 Due: 04/18/19

Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01076335 Org: User:
Start: 05/31/05 End: 06/30/15 Due: 06/30/16

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01740557 Org: User:
Start: 01/28/15 End: 04/21/23 Due: 04/21/24

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT01560949 Org: User:
Start: 06/14/12 End: 02/20/19 Due: 02/20/20